We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Dual Staining Kit Identifies High Grade Cervical Disease

By LabMedica International staff writers
Posted on 07 Jun 2010
A staining test is capable of identifying the underlying causes of high-grade cervical disease among women who are negative on the Papanicolau test (Pap smears). More...


The test uses advanced biomarkers to stain the cervical epithelium of women whose Pap smear results were equivocal but who were positive for Human papillomavirus (HPV). The smears are double stained with two immunoreactive markers revealing diagnostic proteins.

The codetection of the cell cycle regulatory protein p16 INK4a (p16) and a marker for cell proliferation Ki-67 in a single cell can be used as a screening test for high-grade cervical disease. Their presence in a single cell is an indicator of cell cycle deregulation that occurs during High Risk-HPV (HR-HPV) induced oncogenic transformation. The test is highly specific and highly sensitive for women most likely to have this condition. The test can be applied on conventional and liquid based cytology slides where brown cellular staining indicates p16 over-expression and red nuclear staining indicates Ki-67 expression.

In a prospective study of screening for cervical cancer in Germany, 427 women out of nearly 8,000 tested HPV positive when the Pap test was negative. These women were then managed with repeat testing and colposcopic examinations and biopsies as clinically indicated. Cervical smears from the same cases were tested with the dual staining method CINtecPLUS developed by mtm laboratories AG, (Heidelberg, Germany) and compared with the biopsy results. The test detected 91.9% of patients with cervical intraepithelial neoplasia (CIN), grade 2 (moderate dysplasia) and 96% of CIN grade 3 (severe dysplasia) cases.

The test is independent of age and HR-HPV infections. The results of the study were presented in May 2010 at the 5th European Congress of the European Federation for Colposcopy and Cervical Pathology in Berlin, Germany (EFC).

Robert J. Silverman, MA, the CEO of mtm laboratories stated, "the CINtec Plus kit is so accurate in detecting high grade disease in those women tested that they can immediately be followed up, while those who are negative can be triaged for routine testing."

Related Links:

mtm laboratories AG




New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.